Here are the latest stories being discussed in biopharma today:
Nkarta Prioritizes Autoimmune Projects After Cancer Program Disappointment
Nkarta has suspended its lead program after disappointing Phase 1 data on a CAR-NK therapy to combat aggressive leukemia, turning its attention to cell therapy in autoimmune diseases. Although shares dropped 22%, analysts remain optimistic. Recent studies show large potential in this area, for example, lupus patients going into remission after cell therapy.
FDA Approval for Italfarmaco’s Duvyzat
The FDA has approved Italfarmaco’s Duvyzat for Duchenne muscular dystrophy, the first nonsteroidal treatment to combat all genetic variants of the disease. Duvyzat, an oral drug, is a histone deacetylase inhibitor. It seeks to counteract the effects of the lack of dystrophin rather than attempt to restore it. The decision follows promising results from a Phase 3 trial.
GSK Parts with Majority of Bellus Health Employees
GSK has announced the laying off of several staff behind its investigational drug for chronic cough at Bellus Health. The move comes after GSK successfully acquired the Canadian biotech for $2B a year ago. GSK has not disclosed the exact number of roles impacted.
Meiji Seika Pharma to Offer Japan Self-Amplifying mRNA Covid-19 Vaccine in 2024
Japanese company Meiji Seika Pharma plans to apply to supply location with its self-amplifying mRNA Covid-19 in autumn or winter of 2024. Trials have seen a significant and durable reduction in eye pain and other disease symptoms.
Intellia Ends Regeneron Partnership, Sangamo Announces $24M Offer
Intellia has opted out of a collaboration with Regeneron for a Factor IX gene editing therapy. Elsewhere, biotech company Sangamo is offering around 24.7 million shares at 84 cents each.
CEO Retirements and Appointments at Parexel and AffyImmune
Parexel CEO, Jamie Macdonald, will retire on May 15th, with current Chief Operating and Growth Officer, Peyton Howell, taking over the role. Meanwhile, AffyImmune has promoted COO Matt Britz to CEO.
